Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis

Cozzi, Salvatore; Najafi, M. Hassan; Gomar, Marzieh; Ciammella, Patrizia; Iotti, C.; Iaccarino, Corrado; Dominici, Massimo; Pavesi, Giacomo; Chiavelli, Chiara; Kazemian, Ali; Jahanbakhshi, Amin

doi:10.3390/curroncol29020075

Cited by 16 publications

(13 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As it has been shown, adding neoadjuvant treatment may increase overall survival [46]. Among the different modalities for immunotherapy in glioblastoma, dendritic cell vaccination has gathered considerable attention after some encouraging reports showing acceptable efficacy and safety levels [13]. It is well acknowledged that DC immunization improves OS in GBM patients [18,19].…”

Section: Discussionmentioning

confidence: 99%

“…Adopting immunotherapy treatments for other cancers to glioblastoma is possible, and different studies have documented some benefits [6,12,13]. Other researchers have previously shown that 90 percent of GBMs have cytomegalovirus (CMV) antigens, although the normal brain does not [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

“…Even though DC-based immunity treatment for highgrade gliomas (HGGs) appears to be effective, its therapeutic benefit may only apply to a small subset of patients. It is persistently seen as a tail in the overall survival (OS) curve in survival assessments of patients who received vaccinations [13,[17][18][19]. Vaccinations against the heat-shock protein (HSP) promote antigen absorption by antigen-presenting cells and activated T lymphocytes [20].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review

et al. 2023

Self Cite

View full text Add to dashboard Cite

The most prevalent and deadly primary malignant glioma in adults is glioblastoma (GBM), which has a median survival time of about 15 months. Despite the standard of care for glioblastoma, which includes gross total resection, high-dose radiation, and temozolomide chemotherapy, this tumor is still one of the most aggressive and difficult to treat. So, it is critical to find more potent therapies that can help glioblastoma patients have better clinical outcomes. Additionally, the prognosis for recurring malignant gliomas is poor, necessitating the need for innovative therapeutics. Immunotherapy is a rather new treatment for glioblastoma and its effects are not well studied when it is combined with standard chemoradiation therapy. We conducted this study to evaluate different glioblastoma immunotherapy approaches in terms of feasibility, efficacy, and safety. We conducted a computer-assisted literature search of electronic databases for essays that are unique, involve either prospective or retrospective research, and are entirely written and published in English. We examined both observational data and randomized clinical trials. Eighteen studies met the criteria for inclusion. In conclusion, combining immunotherapy with radiochemotherapy and tumor removal is generally possible and safe, and rather effective in the prolongation of survival measures.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…The nonspecific passive immunotherapy includes activated lymphocytes and macrophages. A separate group of adoptive immunotherapy is represented by live immunocompetent cells or their fractions capable of eliciting the cell-mediated immune response to tumor-associated antigens [36,37]. This kind of active specific immunotherapy will be considered in more detail.…”

Section: Vaccines As a Modern Strategy Of Immunotherapymentioning

confidence: 99%

Dendritic Cells in Glioblastoma Treatment: A Modern View of the Problem and Own Experience

Glavatskyi,

Khranovska,

Skachkova

et al. 2023

Exp. oncol.

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive primary malignant brain tumor in adults. The improvement of the efficacy of GBM treatment is an urgent problem encouraging the development of novel therapeutic strategies, in particular, immunotherapeutic modalities. With more understanding of the intimate interrelationships between the immune system and the mechanisms involved in cancer origin and progression, the skepticism related to the relevance of the immunotherapeutic approaches in the treatment of brain tumors is gradually decreasing. The review discloses the modern concepts on the association between CNS and the immune system. For a long time, CNS was considered as the immunoprivileged site that prevents the effects of immunotherapy in the treatment of brain tumors. Nowadays, these views are reconsidered, which opens the way to the use of immunotherapeutic approaches in GBM treatment. The results of the recent clinical trials on immunotherapy as a supplement to the conventional GBM treatment are considered. Vaccines based on the dendritic cell (DC) technology are regarded as the most promising for this purpose. The preliminary results of the Ukrainian clinical study are also presented and discussed. The results of the international clinical trials as well as our own experience give evidence of the relevance for using DC vaccines in the complex treatment of GBM, which is supported by the increased survival of patients and the safety of vaccine application. It is of high importance that GBM patients with the most unfavorable prognosis can benefit from DC vaccines as a component of the complex treatment. The prospects for immunotherapy in neurooncology are discussed.

show abstract

“…Despite the development of new radiotherapy techniques, there are a few new drugs that seem to be effective and safe. Nonetheless, the prognosis remains poor [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Epileptogenesis and Tumorigenesis in Glioblastoma: Which Relationship?

et al. 2022

View full text Add to dashboard Cite

Epilepsy is reported in 29–52% of patients with glioblastoma (GBM) and has an important role in the natural history of this tumor and patients’ life quality. Although GBM is less epileptogenic than lower-grade gliomas, seizures are usually more difficult to control with common antiseizure medications; drug resistance is found in 20% of cases. Recent studies suggest that seizures at the onset of GBM could be a possible favorable independent prognostic factor in patients. Moreover, a growing body of evidence shows that many molecular mechanisms that influence epileptogenesis often regulate GBM growth and invasiveness, sometimes favoring or counteracting the tumor, respectively. The better-characterized players include glutamate, γ-aminobutyric acid, aquaporin-4, and hypoxia-activated molecules. However, currently available data on the molecular basis of epileptogenesis, tumorigenesis, and their relationship is incomplete or discordant and further research is urgently needed on this topic.

show abstract

Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis

Cited by 16 publications

References 47 publications

Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review

Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review

Dendritic Cells in Glioblastoma Treatment: A Modern View of the Problem and Own Experience

Epileptogenesis and Tumorigenesis in Glioblastoma: Which Relationship?

Contact Info

Product

Resources

About